Therapy for small cell lung cancer using carboplatin, ifosfamide, etoposide (without dose reduction), mid-cycle vincristine with thoracic and cranial irradiation

Prendiville, Joseph A; Lorigan, Paul; Hicks, Frank D.; Leahy, B.C.; Stout, Ronald; Burt, Paul A; Thatcher, Nick

doi:10.1016/0959-8049(94)00363-a

Cited by 12 publications

(2 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The VICE regimen has been reported to be active in SCLC and has also been successfully com bined with radiation therapy [24,25], In our study, we used a stepwise reduction of intervals between chemo therapy cycles.…”

Section: Introductionmentioning

confidence: 99%

Dose Intensity Phase l/lI Trial with Carboplatin, Ifosfamide, Etoposide and Vincristine Combined with Filgrastim in Patients with Small-Cell Lung Cancer

et al. 1997

View full text Add to dashboard Cite

Background: The purpose of the study was to evaluate the feasibility of increasing dose intensity by a stepwise reduction of the time intervals between chemotherapy cycles in separate patient cohorts with small-cell lung cancer. Patients received up to 6 courses of combination chemotherapy with carboplatin, etoposide, ifosfamide and vincristine followed by support with filgrastim. Dose intensity, incidence, duration and severity of neutropenic fever and infections, objective response to chemotherapy, and safety of filgrastim were determined. Patients and Methods: 29 patients with small-cell lung cancer (limited disease: 2, extensive disease: 27) were treated with a combination of carboplatin 250 mg/m² i.v. day 1, ifosfamide 2 g/m² and etoposide 120 mg/m² i.v. days 1 and 2, etoposide 120 mg/m² orally day 3, and vincristine 1.4 mg/m² day 14. Initially, filgrastim (5 μg/kg) was administered subcutaneously from day 7 to 16. With shorter treatment intervals, filgrastim was administered on days 4-16 or 4-14. Results: An overall increase in dose intensity by a factor of 1.44 was achieved after reducing the treatment interval from 27 to 17 days. Further reduction to 14 days was not feasible due to persistent thrombocytopenia. Six patients (21%) developed a total of 9 febrile episodes, and 14 patients (48%) had to be withdrawn from the study before the completion of six cycles of chemotherapy. The median duration of infectious episodes was 6 days. Overall, a total of 22 of 27 evaluable patients had an objective response. Longer treatment intervals resulted in a lower probability for objective response (≥23 days: 10/14 patients vs. ≤17 days: 7/7 patients). Conclusion: Filgrastim allows for the reduction of treatment intervals in patients with small-cell lung cancer and increased dose intensity with acceptable hematologic and nonhematologic toxicities.

show abstract

Section: Introductionmentioning

confidence: 99%

Dose Intensity Phase l/lI Trial with Carboplatin, Ifosfamide, Etoposide and Vincristine Combined with Filgrastim in Patients with Small-Cell Lung Cancer

et al. 1997

View full text Add to dashboard Cite

show abstract

“…Combination treatment yields a higher proportion of clinically complete responses than single agent therapy, and two-year survival rates of up to 30% have been reported from the use of ifosfamide, carboplatin and etoposide (ICE) with thoracic radiotherapy for patients with limited disease (Prendiville et al, 1994). There is some evidence from randomized trials that the dose intensity of treatment for SCLC may be important, with modest but definite improvements in survival seen following the use of growth factors to reduce the intervals between cycles of chemotherapy (Steward et al, 1998).…”

mentioning

confidence: 99%

A randomized trial of amifostine as a cytoprotective agent in patients receiving chemotherapy for small cell lung cancer

Johnson

Muers

Peake³

et al. 2001

Br J Cancer

View full text Add to dashboard Cite

Summary A randomized trial was conducted to determine whether administration of Amifostine with chemotherapy for small cell lung cancer could decrease the toxicity. 84 patients with small cell lung cancer of favourable prognosis (limited disease, performance status 0 -1; limited disease with performance status 2 but normal sodium and alkaline phosphatase, or extensive diseas with performance status 0 -1, normal sodium and alkaline phosphatase) received treatment with Ifosfamide 3 g/m 2 intravenously, Carboplatin (Glomerular filtration rate + 25) ϫ6 mg intravenously, Etoposide 50 mg orally, twice daily, for 7 days, every 3 weeks. Patients were randomized to receive amifostine 740 mg/m 2 immediately prior to the intravenous drugs (n = 42) or to receive chemotherapy alone (n = 42). The two groups were similar with respect to baseline prognostic factors. There was no significant difference in the occurrence of grade III or IV neutropenia or thrombocytopenia between the two groups, nor in the response rate or overall survival, for which the median was 11 months in the chemotherapy only group and 14 months in the group treated with amifostine. This study has not shown a protective effect from the use of amifostine with this regimen and there does not appear to be any effect upon the efficacy of treatment.

show abstract

Management of Lung Cancer in Older People

Gridelli¹,

Audisio²

2013

View full text Add to dashboard Cite

Therapy for small cell lung cancer using carboplatin, ifosfamide, etoposide (without dose reduction), mid-cycle vincristine with thoracic and cranial irradiation

Cited by 12 publications

References 19 publications

Dose Intensity Phase l/lI Trial with Carboplatin, Ifosfamide, Etoposide and Vincristine Combined with Filgrastim in Patients with Small-Cell Lung Cancer

Dose Intensity Phase l/lI Trial with Carboplatin, Ifosfamide, Etoposide and Vincristine Combined with Filgrastim in Patients with Small-Cell Lung Cancer

A randomized trial of amifostine as a cytoprotective agent in patients receiving chemotherapy for small cell lung cancer

Management of Lung Cancer in Older People

Contact Info

Product

Resources

About